skip to main content

H.R. 2855: Star Rating for Biosimilars Act


We don’t have a summary available yet.

The summary below was written by the Congressional Research Service, which is a nonpartisan division of the Library of Congress, and was published on Apr 26, 2021.


Star Rating for Biosimilars Act

This bill requires the Centers for Medicare & Medicaid Services (CMS) to establish quality measures regarding biosimilar biological products under the five-star performance rating system for Medicare Advantage plans. The measures must assess the level of access that plans provide to covered biosimilars, including with respect to formularies, cost-sharing, and utilization management.

The CMS must also incorporate such measures into similar rating systems for plans under the Medicare prescription drug benefit.